Intellia Therapeutics (NTLA) Change in Accured Expenses (2015 - 2026)

Intellia Therapeutics (NTLA) has 12 years of Change in Accured Expenses data on file, last reported at -$11.9 million in Q1 2026.

• On a quarterly basis, Change in Accured Expenses rose 17.12% year-over-year to -$11.9 million in Q1 2026; TTM through Mar 2026 was -$2.8 million, a 17.04% decrease from a year earlier, with the FY2025 full-year figure at -$5.3 million, up 49.23% from the prior year.
• Change in Accured Expenses for Q1 2026 stood at -$11.9 million, down from $9.0 million in the prior quarter.
• Over the last five years, Change in Accured Expenses for NTLA reached as high as $13.6 million in Q3 2022 and fell as low as -$22.4 million in Q1 2024.
• Historically, Change in Accured Expenses has averaged -$332529.4 across 5 years, with a median of $3.0 million in 2022.
• Across the five-year window, Change in Accured Expenses surged 220.06% in 2022 and tumbled 367.9% in 2023, its largest moves.
• Year by year, Change in Accured Expenses stood at $3.1 million in 2022, then surged by 194.01% to $9.0 million in 2023, then sank by 56.23% to $4.0 million in 2024, then surged by 128.36% to $9.0 million in 2025, then tumbled by 232.35% to -$11.9 million in 2026.
• Per Business Quant data, the three most recent Change in Accured Expenses figures were -$11.9 million in Q1 2026, $9.0 million in Q4 2025, and -$715000.0 in Q3 2025.